Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
PTGER4 5734 CHEMBL1628262 CHEMBL1628262 agonist GuideToPharmacologyInteractions
PTGER4 5734 MIANSERIN CHEMBL6437 antagonist GuideToPharmacologyInteractions
PTGER4 5734 EVATANEPAG CHEMBL563646 antagonist GuideToPharmacologyInteractions
PTGER4 5734 MISOPROSTOL CHEMBL606 agonist GuideToPharmacologyInteractions, DrugBank 11993717, 18472336, 16039053, 9313928, 11602631, 12097143
PTGER4 5734 CICAPROST CHEMBL160629 agonist GuideToPharmacologyInteractions
PTGER4 5734 ALPROSTADIL CHEMBL495 agonist GuideToPharmacologyInteractions
PTGER4 5734 EPOPROSTENOL CHEMBL1139 agonist GuideToPharmacologyInteractions
PTGER4 5734 CHEMBL357834 CHEMBL357834 agonist GuideToPharmacologyInteractions
PTGER4 5734 CHEMBL591666 CHEMBL591666 antagonist GuideToPharmacologyInteractions
PTGER4 5734 CHEMBL265012 CHEMBL265012 antagonist GuideToPharmacologyInteractions
PTGER4 5734 CHEMBL597997 CHEMBL597997 antagonist GuideToPharmacologyInteractions
PTGER4 5734 CHEMBL1628698 CHEMBL1628698 TdgClinicalTrial
PTGER4 5734 CHEMBL3246389 CHEMBL3246389 agonist GuideToPharmacologyInteractions
PTGER4 5734 CHEMBL239226 CHEMBL239226 agonist GuideToPharmacologyInteractions
PTGER4 5734 TREPROSTINIL CHEMBL1237119 agonist GuideToPharmacologyInteractions
PTGER4 5734 CHEMBL1476810 CHEMBL1476810 agonist GuideToPharmacologyInteractions
PTGER4 5734 CARBACYCLIN CHEMBL148319 agonist GuideToPharmacologyInteractions
PTGER4 5734 DINOPROST CHEMBL815 agonist GuideToPharmacologyInteractions
PTGER4 5734 STREPTOZOTOCIN CHEMBL1651906 NCI 16954344
PTGER4 5734 DINOPROSTONE CHEMBL548 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 18715952, 19788928, 17329241, 20599704, 16545798
PTGER4 5734 BERAPROST CHEMBL1207745 agonist GuideToPharmacologyInteractions
PTGER4 5734 CHEMBL275667 CHEMBL275667 agonist GuideToPharmacologyInteractions
PTGER4 5734 ENPROSTIL CHEMBL2104194 agonist GuideToPharmacologyInteractions
PTGER4 5734 ILOPROST CHEMBL494 agonist GuideToPharmacologyInteractions
PTGER4 5734 CHEMBL215344 CHEMBL215344 agonist GuideToPharmacologyInteractions
PTGER4 5734 CHEMBL304858 CHEMBL304858 antagonist GuideToPharmacologyInteractions
PTGER4 5734 GRAPIPRANT CHEMBL3039498 antagonist GuideToPharmacologyInteractions
PTGER4 5734 CHEMBL402162 CHEMBL402162 antagonist GuideToPharmacologyInteractions
PTGER4 5734 RIVENPROST CHEMBL303960 agonist TTD
PTGER4 5734 BETAMETHASONE CHEMBL632 NCI 17515865
PTGER4 5734 IBUPROFEN CHEMBL521 NCI 9118476

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
PTGER4 rs10512734 GG adalimumab efficacy no After 4 and 12 weeks of treatment, a greater percentage of those with the GG genotype had clinical response to treatment as compared to those with the AA or AG genotype. Clinical response assessed using change in inflammatory bowel disease questionnaire (IBDQ) value. However, this association did not remain significant after correction for multiple testing (p=0.152) Genotype GG is associated with increased response to adalimumab in people with Crohn Disease as compared to genotypes AA + AG. 25712183 1444936497